Posted innews Psychiatry Public Health
Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial
A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, though results were not statistically significant.
